Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.

[1]  L. O. Ticknor,et al.  Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains , 2006, Journal of bacteriology.

[2]  S. Kozaki,et al.  Protective effect of botulinum C/D mosaic toxoid against avian botulism. , 2006, The Journal of veterinary medical science.

[3]  Leonard A. Smith,et al.  Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115. , 2006, Protein expression and purification.

[4]  S. Kozaki,et al.  Characterization of the Neurotoxin Produced by Isolates Associated with Avian Botulism , 2005, Avian diseases.

[5]  Leonard A. Smith,et al.  Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization , 2005, Infection and Immunity.

[6]  M. Lindström,et al.  Type C Botulism Due to Toxic Feed Affecting 52,000 Farmed Foxes and Minks in Finland , 2004, Journal of Clinical Microbiology.

[7]  P. Nol,et al.  PREVALENCE OF NEUROTOXIC CLOSTRIDIUM BOTULINUM TYPE C IN THE GASTROINTESTINAL TRACTS OF TILAPIA (OREOCHROMIS MOSSAMBICUS) IN THE SALTON SEA , 2004, Journal of wildlife diseases.

[8]  Y. Sakaguchi,et al.  Vaccination with Recombinant Whole Heavy Chain Fragments of Clostridium botulinum Type C and D Neurotoxins , 2004, Clinical Diagnostic Laboratory Immunology.

[9]  Roberto Eleopra,et al.  Different types of botulinum toxin in humans , 2004, Movement disorders : official journal of the Movement Disorder Society.

[10]  Leonard A. Smith,et al.  Roads from vaccines to therapies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[11]  J. Keller,et al.  Uptake of botulinum neurotoxin into cultured neurons. , 2004, Biochemistry.

[12]  R. Hirst,et al.  Expression of HC Subunits from Clostridium botulinum Types C and D and Their Evaluation as Candidate Vaccine Antigens in Mice , 2003, Infection and Immunity.

[13]  Leonard A. Smith,et al.  Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A , 2003, The Journal of Biological Chemistry.

[14]  V. Tugnoli,et al.  Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting , 2002, Clinical Neurophysiology.

[15]  M. Friend.  Avian disease at the Salton Sea , 2002, Hydrobiologia.

[16]  L. Smith,et al.  Development of vaccines for prevention of botulism. , 2000, Biochimie.

[17]  R. Titball,et al.  Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. , 2000, Protein expression and purification.

[18]  G. Schiavo,et al.  Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.

[19]  Leonard A. Smith,et al.  Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate , 1998, Infection and Immunity.

[20]  K. Takeshi,et al.  Molecular Composition of the 16S Toxin Produced by a Clostridium botulinum Type D Strain, 1873 , 1998, Microbiology and immunology.

[21]  Leonard A. Smith,et al.  Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. , 1998, Protein expression and purification.

[22]  L. Williamson,et al.  Syntaxin and 25‐kDa synaptosomal‐associated protein: Differential effects of botulinum neurotoxins C1 and A on neuronal survival , 1998, Journal of neuroscience research.

[23]  L. Gomella,et al.  In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  A. Varshavsky,et al.  The N-end rule: functions, mysteries, uses. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Inoue,et al.  Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. , 1996, Biochimica et biophysica acta.

[26]  K. Inoue,et al.  Molecular cloning of the gene encoding the mosaic neurotoxin, composed of parts of botulinum neurotoxin types C1 and D, and PCR detection of this gene from Clostridium botulinum type C organisms , 1996, Applied and environmental microbiology.

[27]  T. Watanabe,et al.  The complete amino acid sequence of the Clostridium botulinum type D neurotoxin, deduced by nucleotide sequence analysis of the encoding phage d-16 phi genome. , 1992, The Journal of veterinary medical science.

[28]  N. Tachi,et al.  Infant botulism due to Clostridium botulinum type C toxin , 1990, The Lancet.

[29]  K. Takeshi,et al.  The complete nucleotide sequence of the gene coding for botulinum type C1 toxin in the C-ST phage genome. , 1990, Biochemical and biophysical research communications.

[30]  H. Kurazono,et al.  Nucleotide sequence of Clostridium botulinum C1 neurotoxin. , 1990, Nucleic acids research.

[31]  K. Moriishi,et al.  Molecular diversity of neurotoxins from Clostridium botulinum type D strains , 1989, Infection and immunity.

[32]  J. Terajima,et al.  Purification and characterization of neurotoxin produced by Clostridium botulinum type C 6813 , 1985, Infection and immunity.

[33]  B. Syuto,et al.  Comparison of antigenicity of toxins produced by Clostridium botulinum type C and D strains , 1984, Applied and environmental microbiology.

[34]  B. Syuto,et al.  Analysis of antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and monoclonal antibodies , 1984, Infection and immunity.

[35]  K. Inoue,et al.  Phage-conversion of toxigenicity in Clostridium botulinum types C and D. , 1971, Japanese journal of medical science & biology.

[36]  C. Dolman,et al.  Clostridium Botulinum Type F with Recent Observations on Other Types , 1961 .

[37]  Wenhui Zhang,et al.  Design of Methanol Feed Control in Pichia pastoris Fermentations Based upon a Growth Model , 2002, Biotechnology progress.